Next-Gen Electrolyte Analyzers with Bio-Sensor Cartridge Technology Simplify Clinical Analysis
|
By LabMedica International staff writers Posted on 10 Jul 2023 |

Electrolytes and metabolites offer valuable insights into the body's metabolic processes. Electrolyte analyzers measure ion concentrations in the blood, such as potassium, sodium, bicarbonate, chloride, calcium, glucose, lactate, and magnesium. This analysis helps identify medical conditions like kidney failure, heart failure, uncontrolled diabetes, hemorrhage, chemical poisoning, drug overdose, shock, asthma, and chronic obstructive pulmonary disease (COPD). One of the significant long-term advancements in the electrolyte analyzer market is the creation of technologically enhanced devices and the utilization of sophisticated sensors for monitoring critical parameters like pH level and electrolyte concentration. Now, next-generation electrolyte analyzers with advanced features enable increased accuracy and productivity while shortening the turnaround time for each sample, and reducing human input errors.
The CBS series, a direct ISE analyzer, from B&E Biotechnology Co. Ltd. (Yantai, China) measures whole blood or serum samples directly without the need for dilution. The CBS series (e.g., the CBS-5) measures pH, K, Na, Cl, iCa, and TCO2, and offer simple module replacement. These analyzers come with a 20-hole sample tray and can test 60 samples per hour. The CBS series is popular in numerous countries worldwide, with approximately 10,000 units currently installed. Additionally, the company also offers the KS series of indirect ISE analyzers (e.g., the KS 401) which can automatically dilute samples up to 20 times for testing and can process up to 120 samples per hour. They offer easy electrode module replacement and have a long module lifespan (10,000 samples or two months of operation). With capabilities such as switching between serum mode and urine mode with a single click, direct total calcium testing, and a 60-hole sample tray, the KS series is particularly suitable for medium-sized hospitals. Due to its small sample size, flexibility, and ease of use, the KS series is also making waves in the global market.
Both the CBS and KS series of analyzers utilize multi-sensor modules developed from B&E's extensive technical experience in multi-biosensor technology (MBT). The modules, comprising ceramic plates and specific ion-selective membrane ingredients, exhibit impressive linearity, reproducibility, and long-term stability. Leveraging its MBT applications, B&E has also developed an electrolyte biosensor unit (EBU) that can be adapted to automatic biochemistry analyzers for electrolyte analysis to dramatically reduce running costs.
Related Links:
B&E Biotechnology Co. Ltd.
Latest Clinical Chem. News
- New Chairside Oral Swab Test Could Guide Biopsy Decisions in Oral Cancer
- Multi-Protein Blood Test Improves Staging of Alzheimer’s Disease
- Blood Biomarker Study Reveals Population-Specific Differences in Alzheimer’s Disease
- AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer
- Compact Prenatal Screening System Expands Access to Preeclampsia Testing
- Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing
- Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients
- Blood Biomarker Reveals Hidden Disability Progression in Multiple Sclerosis
- Machine Learning Model Shows Promise for Improving Metanephrine Testing Accuracy
- Blood Test Enters UK Primary Care Pathway for Earlier Alzheimer’s Diagnosis
- Common HbA1c Assay May Miss Diabetes in People with Sickle Cell Trait
- Blood Protein Panel Predicts Timing of ALS Symptom Onset
- Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
- Preoperative Blood Test Predicts Colorectal Cancer Recurrence and Metastasis
- New Machine-Learning Equation Improves LDL Cholesterol Assessment
- Ultrasensitive Biosensor Detects Early Liver Fibrosis from Blood
Channels
Molecular Diagnostics
view channel
Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation
Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth
Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
Invasive fungal infections disproportionately affect immunocompromised patients, while diagnostic delays can contribute to substantial morbidity and mortality. Existing methods often depend on invasive... Read morePathology
view channel
AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
Molecular profiling is essential for characterizing solid tumors, but many laboratories still rely on separate genetic assays to detect alterations such as TP53 mutations. These workflows can be resource-intensive... Read more
AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
Pathology laboratories face growing case volumes, staffing pressures, and increasing diagnostic complexity that can delay results. At the same time, whole-slide images may contain quality defects such... Read more
FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
Selecting patients for antibody-drug conjugates (ADCs) increasingly requires broader tissue context, as target expression alone may not fully explain therapeutic response. Laboratories and translational... Read more
Standardized Staining Technology Advances Digital Pathology Workflows
Digital pathology is increasingly used to streamline cancer diagnostics, yet staining variability can hinder slide interpretation and limit the reliability of artificial intelligence tools.... Read more
Global Testing Service Advances Leukemia MRD Monitoring
KMT2A rearrangements drive aggressive subsets of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and are associated with relapse and poor outcomes. As menin inhibitors enter clinical... Read more







